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Abstract: Human papillomavirus (HPV) infection is a causative factor for various cancers of the
anogenital region and oropharynx, and is supposed to play an important cofactor role for skin
carcinogenesis. Evasion from immunosurveillance favors viral persistence. However, there is
evidence that the mere presence of oncogenic HPV is not sufficient for malignant progression
and that additional tumor-promoting steps are required. Recent studies have demonstrated that
HPV-transformed cells actively promote chronic stromal inflammation and conspire with cells
in the local microenvironment to promote carcinogenesis. This review highlights the complex
interplay between HPV-infected cells and the local immune microenvironment during oncogenic
HPV infection, persistence, and malignant progression, and discusses new prospects for diagnosis
and immunotherapy of HPV-associated cancers.
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1. Introduction
Approximately 15–20% of all cancers are caused by infectious agents [1] and around 5% by human
papillomaviruses (HPVs) [2,3]. The causal relationship between HPV infection and cervical cancer,
which harbors HPV in up to 99.7% of cases [4], was highlighted by Harald zur Hausen, who was
awarded a Nobel Prize in 2008. In addition to cervical cancer, a significant number of oropharyngeal,
penile, anal, vaginal and vulvar cancers are induced by mucosal HPVs [5–7] and cutaneous HPVs have
been implicated as cofactors in skin cancer development [8,9].
Invasive cancer is not an immediate consequence of HPV infection. HPV-induced carcinogenesis
takes years or decades to occur, and there is increasing evidence that additional tumor-promoting
steps are required [10]. It is widely accepted that effective immune control is required to prevent
persistent HPV infection. Recent studies indicate, however, that chronic inflammation and misled
immune responses in the local immune microenvironment play a critical role during the progression
of precancerous lesions to invasive cancer [11–13]. Thus, the unidirectional view of an immune system
that primarily serves to attack and eliminate HPV-infected and neoplastic cells needs to be revised [14].
While screening programs have greatly reduced the burden of cervical cancer in developed
countries, current diagnostic tests cannot discriminate between lesions that will progress to
invasiveness and those that do not. This results in an overtreatment of high-grade lesions that are
detected during screening [15]. A better understanding of the immunological mechanisms contributing
to HPV-associated cancer development would likely propel not only more accurate diagnosis of
progressing precancerous lesions but also novel immunotherapeutic approaches for HPV-driven
cancers [16].
This review focuses on the current understanding of the complex interplay between
HPV-infected cells and the local immune microenvironment during HPV infection and HPV-associated
carcinogenesis, and discusses novel prospects for diagnosis and immunotherapy.
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2. Human Papillomaviruses in Mucosal versus Skin Carcinogenesis and Immune Control
Human papillomaviruses are non-enveloped double-stranded (ds) DNA-viruses that are
transmitted sexually or by smear infection [17]. More than 200 different HPV types that are contained
within 5 different genera have been characterized [18,19]. HPV-induced pathologies vary from benign
warts and low- and high-grade neoplasia to malignant cancer and depend on respective HPV types
as well as anatomical sites of infection [20]. While almost all cervical cancers are HPV-associated,
64–91% of vaginal, 40–50% of vulvar, 88–94% of anal and 40–50% of penile cancers are HPV-positive [3].
Notably, prevalences of HPV-driven oropharyngeal cancers display larger geographical variations.
The highest prevalence is observed in developed countries, with HPV-positivity rates ranging from
35% up to more than 70% in some regions, and numbers of oropharyngeal cancers have significantly
increased during the last decades [3,5]. 12–15 mucosal HPV types, all belonging to genus α, have been
identified as so-called high-risk HPV (HR-HPV) types [21]. Numerous studies on the HPV life cycle
and on the biology of the mucosal HPV oncogenes E6 and E7 have greatly improved our understanding
of HPV-induced transformation far beyond the mere inactivation of the tumor suppressor proteins p53
and retinoblastoma (for a review see [22]).
Genus β-HPVs have been implicated in ultraviolet (UV) light-induced non-melanoma skin cancer
in patients suffering from the inherited disease Epidermodysplasia verruciformis [23] and a cofactor
role for skin carcinogenesis in the normal population has been discussed (for reviews see [8,9,24]).
Recent data point to an early role of genus-β HPV in skin carcinogenesis. It has been shown that
β-HPV type 8 infection expands the stem cell compartment in Epidermodysplasia verruciformis
patients by suppressing the stemness-repressing microRNA-203 [25], an initial key step in skin
carcinogenesis. Mechanistically, the E6 protein, the major oncoprotein of HPV8 [26], targets the
transcription factor CCAAT/enhancer binding protein (C/EBP)α that serves as a tumor suppressor of
UV-induced carcinogenesis. HPV8 E6 thereby prevents microRNA-203 expression, leading to potent
up-regulation of the epithelial stemness-maintenance factor ∆Np63 (NH2-terminally deleted p63).
∆Np63 in turn promotes proliferation and inhibits differentiation of keratinocytes [25]. This is in
contrast to the E6 protein encoded by mucosal HR-HPV, which suppresses miR-203 via interference
with p53 [27], while the E7 protein suppresses a protein kinase C-dependent pathway [28]. Proliferation
of hair follicle stem cells was also observed in transgenic mice expressing the HPV8 early region under
the control of the keratin 14 (K14)-promoter [29]. Moreover, genus β-HPVs were shown to suppress
UV-induced DNA damage repair; they interfere with Notch-signaling that further contributes to
∆Np63 up-regulation and have anti-apoptotic properties in vitro. Different β-HPVs have oncogenic
potential in transgenic mice, particularly in synergism with UV-light exposure [26,30–35].
In mucosal as well as cutaneous HPV-associated carcinogenesis it is well accepted that the
immune system has an important surveillance function. In immunocompetent individuals, up to
90% of anogenital HPV infections are cleared within two years [36–38] and this is thought to be due
to innate immunity as well as adaptive CD8+ T cell-mediated responses directed against viral early
proteins [39,40]. Conversely, patients with impaired adaptive immunity, such as transplant recipients or
HIV-patients, show higher prevalences of HPV infection and HPV-related diseases, further underlining
the importance of immunosurveillance in HPV-associated carcinogenesis [8,41–46].
HPV infections that escape immune control can persist and a certain proportion progresses
to cancer. Recent studies have shed light on the immune system as a double-edged sword in
HPV-associated carcinogenesis and evidence is increasing that the role of the immune system changes
in a stage-dependent manner. At earlier stages, anti-viral immunity predominates and the virus
has adopted strategies to counteract immunosurveillance in order to establish persistence in the
epithelium. However, at later stages of the disease, HPV-transformed cells reprogram the local
immune microenvironment and rather initiate chronic stromal inflammation, which then serves to
promote progression of precursor lesions to invasive cancer (Figure 1).
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paracrine IL-6. The IL-6/STAT3 and IL-6/C/EBPβ pathways lead to chemokine induction in stromal 
mesenchymal and infiltrating immune cells. As a consequence, myelomonocytic cells expressing 
protumorigenic MMP-9 and Th17 cells are recruited further promoting inflammation. 
Myelomonocytic cells differentiate into functionally impaired dendritic cells or M2 macrophages 
expressing PD-L1 that inhibit cytotoxic T cell responses. IL-6 suppresses NF-κB activity in stromal 
dendritic cells, which are unable to migrate in response to lymph node homing chemokines due to 
low CCR7 chemokine receptor expression. Instead, they are immobilized within the tumor stroma 
and produce MMP-9 locally. IL-12 is expressed only at low levels shifting T helper cell responses 
from Th1 to Th2. Stromal inflammation and immune deviation facilitate progression to invasiveness. 
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Figure 1. Proposed model of human papillomavirus-induced carcinogenesis. Stage-specific interplay
between virally infected keratinocytes and the local immune microenvironment. At early stages,
HPV-infected cells suppress acute inflammation in the epithelium and immune recognition. This allows
escape from immunosurveillance and viral persistence. During progression to invasive cancer
HPV-transformed cells initiate chronic stromal inflammation and immune deviation orchestrated by
paracrine IL-6. The IL-6/STAT3 and IL-6/C/EBPβ pathways lead to chemokine induction in stromal
mesenchymal and infiltrating immune cells. As a consequence, myelomonocytic cells expressing
protumorigenic MMP-9 and Th17 cells are recruited further promoting inflammation. Myelomonocytic
cells differentiate into functionally impaired dendritic cells or M2 macrophages expressing PD-L1 that
inhibit cytotoxic T cell responses. IL-6 suppresses NF-κB activity in stromal dendritic cells, which are
unable to migrate in response to lymph node homing chemokines due to low CCR7 chemokine receptor
expression. Instead, they are immobilized within the tumor stroma and produce MMP-9 locally. IL-12 is
expressed only at low levels shifting T helper cell responses from Th1 to Th2. Stromal inflammation and
immune deviation facilitate progression to invasiveness. HPV: human papillomavirus; IL: interleukin;
STAT3: signal transducer and activator of transcription 3; C/EBP: CCAAT/enhancer binding protein;
MMP: matrix-metalloproteinase; Th: T helper; PD-L1: programmed death-ligand 1; NF: nuclear factor;
CCR: C-C chemokine receptor; CCL: C-C chemokine ligand; IRF: interferon regulatory factor.
3. Immune Escape Paves the Way for HPV Persistence
To maintain a first line of defense against infections agents, skin and mucosal surfaces are
equipped with efficient immune sentinels and immune effector mechanisms [47,48]. Keratinocytes,
the HPV host cells, form stratified epithelia constituting a physical and immunological barrier against
pathogens. They are armed with pathogen recognition receptors, host intrinsic restriction factors and an
arsenal of inflammatory cytokines and chemokines orchestrating local immune responses [49]. While
the epidermal compartment harbors Langerhans cells and distinct subsets of antigen-presenting cells
(APCs) [50], most innate immune cell types including myeloid, dendritic as well as innate lymphoid
cells and adaptive resident lymphocytes are located in the dermis [51].
3.1. Passive Mechanisms of Immune Escape
For productive infection HPV depends on the keratinocyte differentiation program. After having
entered the proliferating basal keratinocytes, HPV gene expression is low and vegetative replication
dramatically increases only in the more differentiated layers of the epithelium that are bound
to desquamate shortly. The minor levels of protein expression in the lower epithelial layers,
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the well-directed non-cytolytic genome amplification restricted to the differentiated layers, and the
lack of a viremic phase in the viral life cycle are thought to passively help the virus escape immune
recognition [52,53]. Thus, HPV has come to an arrangement with the hostile microenvironment and
avoids alerting the immune system.
3.2. Suppression of Cell-Autonomous Immunity and Acute Inflammation in Keratinocytes
Although HPVs encode only a limited number of regulatory genes, they engage various active
strategies to counteract immune recognition and cell-autonomous immune responses at different
levels [54]. Mucosal as well as cutaneous HPV were shown to suppress recognition by the pattern
recognition receptor toll-like receptor 9 [55,56]. Mucosal HPV also specifically inhibits interferon
(IFN) expression, IFN signaling and downstream responses [57–60]. The HPV E6 oncoprotein directly
targets IFN regulatory factor 3 (IRF3) via direct interaction, while E7 interferes with the anti-viral and
pro-apoptotic factor IRF1 [61–64]. Notably, HPV8 has even adapted to an IFN regulatory factor, IRF7,
which is activated by UV-light in skin [65]. IRF7 is expressed in suprabasal keratinocytes and it has
been demonstrated that it increases HPV8 late promoter activity [66]. In contrast, IRF3-activators,
such as dsRNA or RNA bearing 5′ phosphates, efficiently repress HPV8 promoter activity and HPV8
E6 does not counteract the suppressive activity of IRF3 as expected from mucosal HPV-encoded
E6 proteins [66]. The IRF3-induced state of cell-autonomous immunity against cutaneous β-HPV
in keratinocytes was shown to prevail over IRF7 activity. Thus, IRF3 remains an Achilles heel of
this cutaneous virus [66] opening the possibility to use IRF3-activating compounds for anti-viral
immunotherapy against β-HPV infection.
In contrast to RNA- and other dsDNA-viruses like herpes-simplex or vaccinia viruses that activate
the inflammasome in keratinocytes [67], mucosal HPVs rather dampen acute inflammatory responses
in the epithelium. Keratinocytes harboring episomal HPV and cervical cancer cells harboring integrated
HPV genomes display only low cytokine and chemokine expression in vitro [68–70] and in vivo [12,71]
as a direct consequence of HPV oncoprotein-mediated suppression [71–74]. Mechanistically, it was
shown that mucosal HPV oncoproteins target the p300/CBP-associated factor/nuclear factor (NF)-κB
pathway [70,74–76] and abrogate post-translational processing and secretion of the key inflammatory
cytokine interleukin (IL)-1β [77].
In contrast to IL-1β, IL-1α, an intracellularly stored alarmin, is detectable throughout cervical
carcinogenesis [78]. IL-1α appears not to be affected by mucosal HPV and this can be exploited for
novel immunotherapy strategies. Stimulation of cervical cancer cells with the dsRNA analog PolyIC
mimicking dsRNA-virus infection leads to efficient IL-1α release via induction of necroptosis and this
was shown to potentiate dendritic cell activation [79]. Notably, PolyIC-induced necroptosis, IL-1α
release, and dendritic cell activation are completely dependent on the expression of receptor-interacting
protein kinase 3 (RIPK3) in the HPV-transformed cells. In different cervical cancer patients, RIPK3
is expressed at individual levels in the neoplastic cells in situ, which may critically influence their
response to dsRNA treatment. Thus, pre-therapeutic RIPK3 expression levels could be used as a novel
biomarker to predict the response to immunotherapy with dsRNA or dsRNA-analogs [79,80].
Notably, oncolytic viruses are currently under investigation for cancer therapy and it has become
clear that immune activation is an important part of their anti-tumor activity [81]. Whether the
immunostimulatory activity of dsRNA oncolytic viruses requires RIPK3 expression in the target cells
similar to PolyIC is currently unknown and will be interesting to study.
3.3. Suppression of the Recruitment of Professional APC
Professional antigen-presenting cells connect innate and adaptive immunity. APCs migrate
to secondary lymphatic tissues where they encounter specific T cells, which subsequently become
activated and are redirected to the sites of infection. Local factors released from epithelial cells
critically influence recruitment, differentiation and activation of APCs. Although the role of murine
Langerhans cells has been controversially discussed, human Langerhans cells have been shown to
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prime and cross-prime naive CD8+ T cells [82], which are known to be critical for the immune control
of HPV infection.
Evidence is emerging that HPV infection actively interferes with human Langerhans cell
homeostasis in the epidermal compartment. Both cutaneous and mucosal HPV-infected epithelia
harbor only low numbers of Langerhans cells [71,83] and the responsiveness of in vitro-generated
human Langerhans cells to virus-like particles appears to be restricted [84]. Intriguingly, the expression
of chemokines attracting APCs to the epithelium, such as C-C chemokine ligand (CCL)20 and CCL2,
were found to be particularly low in HPV-infected epithelia in vivo and in vitro-studies demonstrated
that this results from HPV oncoprotein-mediated suppression [11,12,71–74]. While mucosal HPV
oncoproteins target the Langerhans attracting chemokine CCL20 by interfering with the NF-κB
pathway [74], cutaneous β-HPV employ a different strategy to suppress CCL20 [71]. In skin, stress
signals like UV-light can lead to the depletion of Langerhans cells from the epidermis [85]. Subsequent
epithelial up-regulation of the chemokine CCL20 leads to C-C chemokine receptor 6 (CCR6)-dependent
repopulation of the skin with CD1a+ Langerhans cell precursors [86]. In normal human keratinocytes,
the differentiation-associated transcription factor C/EBPβ has been identified as a novel regulator
of CCL20 expression and in human skin. Both C/EBPβ and CCL20 are expressed in the uppermost
nucleated epithelial layers. In HPV8-infected skin, however, CCL20 is almost lacking. It has been
shown that the HPV8 E7 oncoprotein directly interacts with C/EBPβ in keratinocytes and interferes
with its binding to chromatin within the CCL20 promoter region. This suppresses CCL20 expression.
As a consequence, Langerhans cell migration is inhibited preventing repopulation of the epithelium
with these important APCs [71].
Thus, HPV infection actively suppresses cell-autonomous viral recognition and acute
inflammatory signaling in the host keratinocyte as well as recruitment of epithelial APCs. The low
levels of inflammatory cytokines produced by HPV-infected cells may further contribute to the lack of
APC activation, eventually allowing the virus to escape from local immunosurveillance and to persist
in the epithelium.
4. Immunopathogenesis of Transforming HPV Infection during Progression to Invasive Cancer
4.1. Chronic Stromal Inflammation during Progression to Cancer
There is ample evidence that oncogenic HPV infection in the human cervix and skin starts with
expansion of the epithelial stem cell compartment [25,87], which may provide a particularly vulnerable
and immune privileged milieu [88–90]. Moreover, HPV blocks acute NF-κB- and C/EBPβ-dependent
inflammatory signaling in host keratinocytes as outlined above. In persistent low-grade lesions
inflammatory cells are barely detectable.
However, with increasing dysplasia a dramatic increment of stromal infiltration with immune
cells is noted in cervical patient biopsies [11–13,83,91]. From other cancers it has become clear that
chronic inflammation can fuel immune deviation [14,92–94] and the selection pressure set by the
local microenvironment can greatly impact the outcome of the neoplastic process [95]. Since HPV
oncoproteins suppress acute inflammatory responses [71–74,76] and HPV-positive cancer cells produce
only low chemokine levels [68,69,96], the mechanisms underlying immune cell recruitment remained
unclear for a long time.
4.2. Paracrine IL-6 Instructs Myelomonocytic Cells to Create a Pro-Tumorigenic and Immunosuppressive
Microenvironment in Cervical Carcinogenesis
A clue came from the observation that HPV-transformed cells potently up-regulate
chemoattractants in the tumor stroma [11,12]. In monocytes they induce CCL2 production in the
nanogram range [11]. This is supposed to attract further myelomonocytic cells and to sustain the
inflammatory microenvironment via a CCR2-dependent autocrine amplification loop. Strikingly, CCL2
also leads to a tremendous production of the matrix-metalloproteinase (MMP)-9 in monocytes via
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intracellular Ca2+-signaling. MMP-9 has been detected in monocytes starting to infiltrate cervical
high-grade lesions at the switch to malignancy [11]. Local production of MMP-9 is a particularly
interesting consequence of CCL2/CCR2 stimulation. It can promote vasculogenesis and trigger
the angiogenic switch during carcinogenesis required for tumor growth [97]. Transgenic mouse
models have provided evidence that myeloid cell-derived MMP-9 expression promotes HPV-driven
carcinogenesis, and blockage of MMP-9 strongly impairs HPV oncogene-driven carcinogenesis in
mice [98,99]. Importantly, in cervical cancer patients high MMP expression correlates with a poor
prognosis [100].
Neutralization experiments revealed that HPV-transformed cells induce CCL2 and subsequent
MMP-9 expression in monocytes via a combination of IL-6 and macrophage colony-stimulating factor
(M-CSF). They activate the janus kinase/signal transducer and activator of transcription 3 (JAK/STAT3)
signaling pathway in monocytes and various JAK/STAT3-inhibitors are able to interfere with this
pro-tumorigenic response [11].
During productive infection HPV suppresses IL-6 similar to other cytokines [70]. However, both
“switch factors” IL-6 and M-CSF, that are necessary for the pro-tumorigenic response in monocytes,
are highly up-regulated during later stages of human cervical carcinogenesis in situ [69,101]. Clinically
most relevant, IL-6 expression is associated with a negative prognosis for cervical cancer patients [102]
further highlighting its pivotal role in linking chronic inflammation and progression to invasive
cancer [103].
Stromal myelomonocytic cells can either differentiate into dendritic cells, APCs destined to mount
adaptive immune responses, or into macrophages, tissue-resident phagocytes. For the initiation of
adaptive immunity, dendritic cells have to mature as indicated by surface expression of CD83, to
up-regulate major histocompatibility complex class I and II required for antigen presentation as well as
co-stimulatory molecules such as CD80 and CD86 required for T-cell activation, and finally to produce
cytokines that polarize T helper 1 (Th1) cells required for efficient CD8+ cytotoxic T cell responses.
Under normal conditions, the migration receptor CCR7 becomes expressed on their surface during
maturation, ensuring their responsiveness to lymph node homing chemokines [104,105]. A second
migration factor, MMP-9, is needed to allow migration through the extracellular matrix [106,107].
In cervical cancer patients, mature CD83+ dendritic cells are present in the tumor stroma. However,
they were found to be largely devoid of CCR7 expression [13]. As the underlying mechanism, it was
shown that cervical cancer cells actively interfere with NF-κB activation in CD83+ phenotypically
mature dendritic cells. As a consequence, expression of the chemokine receptor CCR7 is suppressed
in the dendritic cells and their migration towards lymph node homing chemokine is blocked [13].
This may lead to an impaired antigen transport to secondary lymphoid tissues by stromal dendritic
cells in cervical cancer patients. Moreover, in high-grade lesions and invasive cancers only low
IL-12p40 expression levels required to mount Th1 responses and a shift from Th1 to Th2 responses are
observed [108,109].
In contrast to CCR7, MMP-9 is potently up-regulated in immature and mature dendritic cells.
Notably, both CCR7 and MMP-9 up-regulation are mediated by IL-6 from the cervical cancer
cells [13,110]. Thus, cervical cancer-derived IL-6 immobilizes dendritic cells in the tumor stroma
via CCR7 suppression facilitating local MMP-9 production.
In cervical cancer stroma M2-polarized macrophages accumulate with low IFN-γ production
and a low capacity to stimulate T cell proliferation [111]. M2 macrophages are also supposed to
have a negative impact on cervical cancer therapy, such as therapy with immunoglobulin G (IgG)
antibodies directed against epidermal growth factor receptor (EGFR) [112]. Notably, anti EGFR-specific
IgA antibodies may overcome this obstacle, since they can engage tumor-associated myeloid cells
for tumor cell killing [113]. This may provide a clear advantage for treatment of M2-infiltrated
tumors and therefore IgA antibodies might represent a novel future category of antibodies for targeted
tumor therapy.
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Besides neoplastic cells, M2-polarized macrophages were also found to express the programmed
death-ligand 1 (PD-L1) [114]. There is clear evidence that cytotoxic T-lymphocyte-associated protein
(CTLA)-4/CD28 and PD-1/PD-L1 interactions between T cells and other cells exert suppressive signals
(immune checkpoints) limiting T cell function and maintaining self-tolerance. This has led to regulatory
approval and successful implementation of blocking antibodies targeting CTLA-4, PD-1, and PD-L1
for the treatment of different malignancies. PD-1 was detected on most infiltrating CD8+ T cells in
cervical cancer [115] suggesting that M2 macrophages might contribute to suppression of cytotoxic
T cell responses. Preliminary studies with the PD-1 blocker pembrolizumab, however, showed only
low response rates in cervical cancer patients with advanced disease. Currently, predictive biomarkers
allowing more precise patient selection are still lacking and it is expected that efficacy might increase
when these blockers are applied in combination with other immunotherapies, such as therapeutic
vaccines [16,116]. Notably, it has been shown that M2 macrophage differentiation is driven by cervical
cancer-derived IL-6 together with prostaglandin E2 [111].
From these studies evidence is increasing that paracrine IL-6 as well as subsequent STAT3
activation and NF-κB suppression are central for reprogramming myelomonocytic cells creating
a pro-tumorigenic and immunosuppressive microenvironment in cervical carcinogenesis. As a
consequence, phenotypically mature but functionally impaired dendritic cells and macrophages
are actively retained in the tumor stroma and this may (1) prevent the initiation of anti-tumoral
adaptive Th1 immune responses; (2) suppress cytotoxic T cell activity; and (3) contribute to an aberrant
local expression of MMP-9 that promotes tumor growth and vasculogenesis. This suggests that the
IL-6/JAK/STAT3 signaling pathway might be an interesting target to revert immune deviation in
cervical cancer. In fact, the IL-6/JAK/STAT3 signaling pathway is “druggable” at various levels [117]
and clinical trials for different cancer entities are ongoing (see clinicaltrials.gov).
4.3. Paracrine IL-6 Induces CCL20 Chemokine Expression in Stromal Mesenchymal Cells to Support
Th17 Recruitment
In human biopsies of cervical carcinogenesis, enhanced infiltration of Th17 cells is observed
with increasing stages of disease and this correlates with up-regulation of CCL20 expression in the
stromal mesenchymal compartment [12]. It is well known that Th17 recruitment is mediated by
CCL20 in a CCR6-dependent manner [118]. Th17 infiltration starts in precursor lesions, and in
invasive cancers a high Th17/Treg ratio is observed [119,120]. Th17 cells are a particular subset of
the CD4+ T cell lineage that can exert either regulatory or inflammatory functions [121]. In various
different cancers Th17 cells promote tumor growth, angiogenesis and also the recruitment of further
inflammatory immune cells [122–124]. Mechanisms underlying stromal CCL20 expression remained
unclear until cervical cancer explant cultures revealed that cancer-associated fibroblasts produce
enormous amounts of CCL20 [12]. These fibroblasts display an activated phenotype characterized
by enhanced C/EBPβ expression. C/EBPβ is also known as the NF-IL6 transcription factor and
is inducible by pro-inflammatory cytokines like IL-6 [125]. Recently, C/EBPβ has been identified
as a novel transcriptional regulator of CCL20 [71]. Thorough analysis demonstrated that cervical
cancer-derived IL-6 drives C/EBPβ-mediated CCL20 induction in cancer-associated fibroblasts and
CCL20/CCR6-dependent Th17 recruitment [12]. This further substantiates the key role of paracrine
IL-6 in cervical carcinogenesis for the initiation and maintenance of chronic inflammation and
tumor progression.
These studies provided evidence that paracrine IL-6 shapes a proinflammatory and
immunosuppressive microenvironment in cervical carcinogenesis via activation of two pathways
in stromal immune and stromal mesenchymal cells, the JAK/STAT3 and the C/EBPβ signaling
pathway. In HPV-driven carcinogenesis, IL-6-induced JAK/STAT3- and C/EBPβ-driven stromal
inflammation may play a key role in promoting tumor progression. At the same time paracrine IL-6
can limit NF-κB-dependent anti-viral and anti-tumor immune responses in APCs, further highlighting
IL-6 as an attractive target for adjuvant immunotherapy of cervical cancer.
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4.4. Regulation and Consequences of Epithelial JAK/STAT3 Pathway Activation in HPV-Induced Carcinogenesis
In HPV-driven carcinogenesis STAT3 is not only activated in the tumor microenvironment. Also,
epithelial cells in cervical high-grade lesions display strong pTyr705-STAT3 activation by far exceeding
activation levels in normal exocervical epithelium or low-grade lesions [11,126]. Studies with transgenic
mice expressing the HPV8 early region under the K14-promoter have provided evidence that epithelial
STAT3 activation is necessary for HPV8-driven skin tumorigenesis [127] and this may also apply to
human HPV-associated carcinogenesis at other body sites.
Notably, in invasive cervical cancers STAT3 activation is often retained at the tumor margin
adjacent to the stroma, while in other parts of the tumor STAT3 activation declines compared to
cervical high-grade lesions [126]. This suggests a paracrine mode of STAT3 activation at the tumor
invasive margin. The overall decline of STAT3 activity in cervical cancer cells can be explained
by a decline of the IL-6 binding receptor chain gp80 in cervical cancer cells [69]. Correspondingly,
non-malignant HPV-transformed cells strongly respond to IL-6 alone. In cultured cervical cancer
cells, however, efficient STAT3 activation can only be elicited by IL-6 in the presence of soluble gp80
(sgp80) [69,126,128].
Strikingly, when the IL-6/STAT3-signaling pathway is activated in cervical cancer cells, they
are more efficiently killed by chemotherapeutic drugs, such as cisplatin or etoposide [126]. This was
unexpected, since in various other human malignancies STAT3 activation promotes tumor growth
and resistance to chemotherapy [129]. As the underlying mechanism, dramatic up-regulation of the
pro-apoptotic factor IRF1 has been identified [126]. Obviously, IL-6/STAT3-induced IRF1 activity
prevails over the HPV oncogene-mediated inhibition of IRF1 [61–63]. Of most clinical relevance,
epithelial IRF1 expression in pre-therapeutic biopsies of cervical cancers significantly correlates
with the patient‘s response to chemo- or radiochemotherapy [126]. This strongly indicates that
pre-therapeutic IRF1 expression could be of high value as a novel biomarker to predict response to
chemo- or radiochemotherapy in patients [126].
In summary, targeting the IL-6/JAK/STAT3-pathway emerges as a promising way to improve
the immune microenvironment in cervical carcinogenesis. However, recent data suggest that these
compounds can also interfere with STAT3-induced IRF1 expression in HPV-positive cancer cells,
thereby increasing their resistance to chemo- or radiochemotherapy. Therefore, the timing of
IL-6/JAK/STAT3-inhibitor administration during therapy appears to be of critical importance. They
should not be applied prior to but rather after chemo- or radiochemotherapy of HPV-driven cancers.
5. Conclusions and Prospects for Diagnosis and Immunotherapy
Over recent years it has become evident that the local microenvironment and particularly the
immune system plays a pivotal role in carcinogenesis [93,94]. In various cancer types it has been
shown that immune cells have a significant prognostic impact, and in colon cancer an “immunoscore”
quantifying in situ immune cell infiltrates seems to be superior to the TNM classification [130,131].
Moreover, immune checkpoint inhibitors interfering with PD-1 or CTLA-4 pathways were recently
shown to improve therapy response rates in various cancers including melanoma, non-small cell
lung cancer, head and neck cancer, renal cell carcinoma and Hodgkin’s lymphoma, and numerous
clinical trials are ongoing [132]. This has also changed the virologist’s view on cancer progression
from the strict focus on viral oncogenes necessary for carcinogenesis to a more complex view of the
interaction between tumor viruses, the immune system and the tumor microenvironment in promoting
cancer progression.
In HPV-induced carcinogenesis, there is now ample evidence for a stage-specific interplay between
virally-infected keratinocytes and the local immune microenvironment that can determine the course
of disease (Figure 1). This knowledge will pave the way for (1) novel diagnostic tools including
immunoscores that allow the discrimination of non-progressing and progressing precursor lesions;
(2) novel biomarkers that improve the prediction of therapy response, such as IRF1, which indicates
response to chemo- or radiochemotherapy; and (3) novel immunotherapeutic approaches beyond
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checkpoint inhibitors that target critical stage-specific mechanisms and pathways in HPV-driven
carcinogenesis. These include IRF3-activating compounds such as dsRNA to combat oncogenic
β-HPV infection, dsRNA-based immunotherapies for patients with high intratumoral RIPK3 levels,
IgA-based antibody therapies that engage myeloid cells for tumor cell killing, and last but not least
IL-6/JAK/STAT3-pathway blocking regimens for cervical cancer patients after treatment with chemo-
or radiochemotherapy.
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